This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds. (NCT03780244), a randomized na study. The primary outcome is Change in Wrinkle Assessment Scale (WAS) Score.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT03780244 |
| Phase | NA |
| Condition | Nasolabial Folds |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Single |
| Enrollment | 80 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Galderma R&D |
| Results posted | Yes |
2. Clinical Question
Population
People with nasolabial fold contour deficiencies are the target population described by the study. The registry record does not report eligibility details such as age ranges, baseline severity requirements, or other participant characteristics.
Intervention
The investigational study product was Sculptra Aesthetic reconstituted with 8ml sterile water for injection. The study summary describes an evaluation of safety and effectiveness after changes in reconstitution and injection procedures compared with the approved label.
Comparator
The reference product was Sculptra Aesthetic reconstituted with 5ml sterile water for injection. The comparison is between two reconstitution volumes of the named product, rather than between treatment and no treatment.
Primary question
The primary outcome was change from baseline in Wrinkle Assessment Scale score at 48 weeks after the first treatment session. The outcome definition concerns both sides of the face, with wrinkle severity assessed by a blinded evaluator.
Statistically, the intended question is whether the recorded change in facial fold severity differs between participants assigned to the two product preparations. The registry record does not report the primary outcome estimates, confidence intervals, or a between-group comparison, so the size and precision of any difference cannot be described from this record. It also does not report the analysis population or the statistical model used for the endpoint. The study is listed as randomized and evaluator-blinded, but details such as the randomization procedure and who else was masked are not reported in the registry record. The stated enrollment is 80. That number describes enrollment, not the number with a measured primary outcome at the specified follow-up.
3. Trial Design
The study is listed as randomized, parallel, and single-masked, and its official title describes it as evaluator-blinded and multicenter. It compared Sculptra Aesthetic reconstituted with 8ml sterile water for injection, called the Investigational Study Product, with Sculptra Aesthetic reconstituted with 5ml, called the Reference Product. Both arms therefore involved the named product, prepared using different reconstitution volumes. The registry summary frames the study as an evaluation of safety for a single regimen after changes in reconstitution and injection procedures compared with the approved label.
Enrollment was 80. The study is recorded as completed, with a start date of 2018-12-18 and primary completion date of 2020-02-28. The phase is listed as NA. The registry record does not describe the randomization sequence, allocation concealment, the allocation ratio, the number of participating centers, treatment duration, or whether additional treatments were permitted. Although the title calls the study evaluator-blinded and the masking entry says single, the identity of all masked parties is not reported in the registry record.
The safety results use denominators of 59 for the Investigational Study Product and 21 for the Reference Product. These are the group sizes used for the displayed safety outcomes; the registry record does not explain why they differ or whether they represent all randomized participants, all treated participants, or another safety population. The primary endpoint is defined as change in Wrinkle Assessment Scale score at 48 weeks after the first treatment session. No numerical primary endpoint result or efficacy comparison is reported in the registry record. The listed secondary outcomes include additional wrinkle, global aesthetic, FACE-Q, and satisfaction measures, but their numerical results are not available in the record analyzed.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Investigational Study Product | Reference Product |
|---|---|---|
| STARTED | 59 | 21 |
| COMPLETED | 58 | 21 |
| NOT COMPLETED | 1 | 0 |
Reasons for not completing this period:
| Reason | Investigational Study Product | Reference Product |
|---|---|---|
| Lost to Follow-up | 1 | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Investigational Study Product | Reference Product | Total |
|---|---|---|---|---|
| Participants analysed | 59 | 21 | 80 | |
| Age, Continuous | years | 51.6 (SD 10.49) | 51.4 (SD 9.93) | 51.5 (SD 10.28) |
| Sex: Female, Male: Female | Participants | 56 | 20 | 76 |
| Sex: Female, Male: Male | Participants | 3 | 1 | 4 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 12 | 6 | 18 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 47 | 15 | 62 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Region of Enrollment: United States | participants | 59 | 21 | 80 |
| Fitzpatrick Skin Type (FST): FST I | Participants | 2 | 0 | 2 |
| Fitzpatrick Skin Type (FST): FST II | Participants | 11 | 6 | 17 |
| Fitzpatrick Skin Type (FST): FST III | Participants | 25 | 12 | 37 |
| Fitzpatrick Skin Type (FST): FST IV | Participants | 9 | 2 | 11 |
| Fitzpatrick Skin Type (FST): FST V | Participants | 9 | 1 | 10 |
| Fitzpatrick Skin Type (FST): FST VI | Participants | 3 | 0 | 3 |
6. Primary Endpoint
The registry lists the primary outcome as Change in Wrinkle Assessment Scale (WAS) Score, measured over 48 weeks.
| Element | Registry entry |
|---|---|
| Result type | Mean |
| Measure of spread | 95% Confidence Interval |
| Unit | units on a scale |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is change from baseline in Wrinkle Assessment Scale score at 48 weeks after the first treatment session, assessed on both sides of the face. The instrument is described as a validated, photograph-based measure designed specifically to quantify facial folds. In this study, the grade was assigned through a live visual assessment by a blinded evaluator at defined time points, rather than by comparing the participant’s appearance with a baseline photograph.
The scale grades nasolabial fold wrinkle severity from 0 to 5. A grade of 0 represents no wrinkles, while 5 represents very deep wrinkles and a redundant fold. The endpoint uses the change in score to describe how the measured severity differs from baseline at the specified follow-up. A mean is a way to summarize the average change across participants; it does not describe every participant’s experience or the spread of individual changes. The registry specifies a 95% confidence interval as the dispersion measure, but does not report the endpoint’s mean change or interval limits.
This endpoint is relevant to the stated study question because it quantifies the facial fold feature the treatment is intended to address. The evaluator-based scoring is intended to provide a structured assessment using a defined scale. However, the registry record does not report scoring reliability, evaluator training, or the details of how scores from the two sides of the face were incorporated into the analysis. It also does not report a numerical comparison between treatment groups. Consequently, the endpoint definition describes what was intended to be measured, not the observed result.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies a randomized comparison and defines a primary outcome, but it does not report numerical results for that outcome. There is no posted mean change for either group, no confidence interval for a group estimate, and no reported between-group effect estimate or test result. The effectiveness question therefore cannot be answered from the outcome information in this record. In particular, the endpoint description is not evidence of the direction or size of change, and a planned assessment at 48 weeks is not itself an observed finding.
The stated endpoint is a mean change in a graded severity measure. General statistical interpretation: a mean summarizes the average observed change, while a confidence interval communicates uncertainty around an estimate under the assumptions of the analysis. A narrower interval is more precise than a wider one, but the interval does not show the range of individual participant responses. Since no estimate or interval is reported, neither the magnitude nor precision of the primary outcome can be assessed.
The safety entries describe participants affected in each registry group. For serious adverse events, the record reports 2 affected participants among 59 in the Investigational Study Product group and 0 among 21 in the Reference Product group. For other adverse events, it reports 7 affected participants among 59 and 7 among 21, respectively. Deaths are recorded as 0 in both groups. Retinal detachment and anxiety are each listed among the top serious adverse event terms at 1.7%. These entries do not establish that a product caused an event, and the record does not supply event narratives, timing, severity grading, or an adjusted comparison.
The unequal safety denominators should be kept in mind when reading the counts. A count alone does not convey the probability of an event, and the registry does not explain the population behind those denominators. A formal comparison would also need to account for the study design and the definitions used to collect and classify adverse events. No such statistical safety comparison is reported in the registry record.
The record lists 18 outcome measures, including secondary measures of wrinkle assessment, global aesthetic improvement, FACE-Q appraisal, and satisfaction. A list of outcomes is not equivalent to numerical results. Without estimates, uncertainty measures, analysis populations, or a prespecified testing strategy, the secondary outcome list cannot establish how the groups compared or how robust any apparent pattern would be. The statistical interpretation is therefore limited to describing the design, endpoint definitions, and reported safety counts. It cannot support a conclusion about the magnitude, precision, or clinical importance of effectiveness differences.
9. Statistical Methods Explained
The following statistical explanations are general unless they describe a specific feature recorded for this study. The registry identifies the primary outcome as a mean change in Wrinkle Assessment Scale score and names a 95% confidence interval as its dispersion measure. It does not report the numerical estimate, interval limits, or the method used to calculate them.
What does a mean change describe?
For a continuous measure, a change score expresses how a participant’s follow-up measurement differs from that participant’s baseline measurement. The mean change summarizes those individual changes across the participants included in an analysis. It is distinct from a follow-up score alone: the change incorporates baseline information, while the follow-up score describes the measured value at that time point. The registry defines effectiveness using change from baseline on both sides of the face at 48 weeks after the first treatment session. It does not explain whether side-specific scores were averaged, analyzed separately, or otherwise combined.
General explanation: the mean can be useful for comparing average outcomes between groups, but it can conceal variation. Participants may have different baseline scores and different changes, even if their group mean is similar. A mean also can be influenced by unusually large or small values. The record does not provide distributions, standard deviations, or participant-level results with which to assess these features.
How should a confidence interval be read?
General explanation: a confidence interval is an estimate paired with a range that reflects statistical uncertainty under the procedure’s assumptions. It is not a range containing a fixed proportion of individual outcomes. Its width depends on factors such as the amount of information available and the variability of measurements. For a group comparison, the interval around the difference is especially useful because it describes both the estimated contrast and its precision. The registry says the primary outcome is presented with a 95% confidence interval, but no interval values or comparison estimate are reported. It is therefore not possible to assess precision or whether a range of effects remains compatible with the data.
Why does the endpoint definition matter?
The Wrinkle Assessment Scale is graded from 0, meaning no wrinkles, to 5, meaning very deep wrinkles with a redundant fold. The record describes a live visual assessment by a blinded evaluator, not a rating based on comparison with baseline appearance. This distinction matters because an absolute severity grade at follow-up and a judgment of change are different measurements. The primary endpoint is explicitly defined as change from baseline, which requires baseline and follow-up measurements. The record does not state how missing measurements were handled or whether the score was treated as continuous in the analysis beyond describing the parameter as a mean.
General explanation: when an outcome is measured on both sides of a participant’s face, those measurements may be related because they come from the same person. Statistical methods commonly need to respect such within-participant dependence rather than treating all measurements as independent. The registry record does not report how the two sides were represented in the analysis, so no particular method can be attributed to this study.
What does randomization contribute?
General explanation: random assignment is intended to make treatment groups comparable, on average, with respect to measured and unmeasured characteristics. It does not guarantee identical groups, especially in a finite study, and it does not replace reporting of baseline characteristics or analysis details. The registry identifies the study as randomized but does not report the sequence-generation method, concealment procedures, or an allocation ratio. The safety denominators are 59 and 21, but the record does not explain how these relate to randomization or the primary analysis population.
What can planning calculations tell readers?
The registry describes sample-size calculations as planning illustrations based on the observed effect, not as the trial’s own design. The stated assumptions are a two-sided significance level of 0.05, equal allocation, a normal approximation, and an effect to detect expressed as a stated fraction of the observed effect. These calculations are not observed power and do not show the probability that the study detected a true effect. They are illustrative planning quantities, and the record does not report that those assumptions governed the original trial design. The registry also does not report the protocol’s sample-size justification or an effect estimate that would permit interpreting an observed-effect-based illustration.
General explanation: planning sample sizes depend on the target effect, variability, significance criterion, desired power, and allocation assumptions. Changing any of these can change the planning result. A calculation that uses an observed effect can be especially difficult to interpret as a forward-looking design rationale because the observed estimate is itself uncertain. No sample-size figure or original design justification is reported in the registry record.
What analysis details remain unknown?
The registry record does not report the model for the primary endpoint, the handling of repeated measurements, covariate adjustment, the test used for the between-group comparison, or the analysis population. It does not report whether interim analyses were planned or conducted. These omissions prevent a detailed reconstruction of the statistical analysis. General explanation: an analysis plan identifies how outcomes, participants, missing observations, and multiple comparisons will be handled. Prespecification helps readers distinguish planned analyses from choices made after observing results. The record does not report such a plan, so none should be inferred.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 18 outcome measures. The primary outcome is change in Wrinkle Assessment Scale score at 48 weeks, while listed secondary outcomes include wrinkle scores, subject and investigator global aesthetic improvement assessments, FACE-Q appraisal, and several satisfaction questions. Testing many outcomes can increase the chance of observing at least one apparently notable result by chance. General statistical practice may address this through prespecified outcome hierarchies, adjustment procedures, or a clearly exploratory interpretation. The registry record does not report a multiplicity strategy, a hierarchy among secondary outcomes, or which outcomes were designated for formal testing.
The record does not provide numerical primary or secondary outcome results, so the consequences of multiple testing cannot be evaluated. It also does not report a complete statistical analysis plan. Interim analyses and any associated decision rules are not reported in the registry record. The 18 listed measures should therefore be read as outcome definitions, not as evidence that each was analyzed or that a particular testing procedure was used.
Missing-data handling and analysis populations are also not reported. The record does not state how many participants contributed primary endpoint measurements, how missing follow-up scores were addressed, or whether the analysis included all randomized participants, treated participants, or another defined group. The enrollment of 80 does not establish the number included in the endpoint analysis. The safety denominators are reported separately, but the registry does not explain their relationship to randomization or to the effectiveness population. These details matter because exclusions and missing measurements can affect both the estimate and its uncertainty. Without them, readers cannot assess attrition, the assumptions used for incomplete data, or whether the reported safety and efficacy populations were aligned.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Investigational Study Product | 2 | 59 | 3.4% |
| Reference Product | 0 | 21 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Investigational Study Product | 0 of 59 |
| Reference Product | 0 of 21 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Investigational Study Product | 7 of 59 |
| Reference Product | 7 of 21 |
Most frequent serious adverse event terms
| Event term | Organ system | Investigational Study Product | Reference Product |
|---|---|---|---|
| Retinal detachment | Eye disorders | 1 of 59 | 0 of 21 |
| Anxiety | Psychiatric disorders | 1 of 59 | 0 of 21 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Investigational Study Product | Reference Product |
|---|---|---|---|
| Headache | Nervous system disorders | 1 of 59 | 2 of 21 |
| Hypoesthesia oral | Gastrointestinal disorders | 1 of 59 | 1 of 21 |
| Rhinorrhea | Respiratory, thoracic and mediastinal disorders | 0 of 59 | 2 of 21 |
| Oral disorder | Gastrointestinal disorders | 1 of 59 | 0 of 21 |
| Injection site hypoaesthesia | General disorders | 1 of 59 | 0 of 21 |
| Injection site paraesthesia | General disorders | 1 of 59 | 0 of 21 |
| Injection site induration | General disorders | 1 of 59 | 0 of 21 |
| Injection site nodule | General disorders | 0 of 59 | 1 of 21 |
| Injection site pain | General disorders | 0 of 59 | 1 of 21 |
| Swelling | General disorders | 0 of 59 | 1 of 21 |
Serious events with the highest arm-level rate: retinal detachment (1.7%), anxiety (1.7%).
The registry reports serious adverse events and other adverse events by safety group. In the Investigational Study Product group, 2 participants among 59 were affected by serious adverse events, and 7 among 59 were affected by other adverse events. In the Reference Product group, 0 participants among 21 were affected by serious adverse events, and 7 among 21 were affected by other adverse events. Deaths are recorded as 0 in each group. The serious event terms listed at the top are retinal detachment and anxiety, each reported at 1.7%.
These counts describe what the registry records; they do not by themselves establish whether an event was caused by treatment. The denominators are not equal, and the record does not describe why they differ or define the safety population in further detail. A count of affected participants is also different from a count of all event episodes if one participant experienced more than one event. Event timing, severity, duration, relatedness assessment, and individual narratives are not reported in the registry record. No adjusted safety comparison or statistical uncertainty measure is reported. The figures should therefore be interpreted descriptively, not as a causal or definitive comparison between preparations.
12. What the Result Does, and Does Not, Mean
The study’s primary endpoint addresses a defined measurement question: how Wrinkle Assessment Scale scores changed from baseline to 48 weeks after the first treatment session. The trial design compares two reconstitution volumes of Sculptra Aesthetic, with evaluator blinding described in the title. Those design features establish the intended comparison, but they do not reveal the observed effectiveness result. The registry record does not report numerical primary endpoint estimates or a between-group contrast.
As a result, the available information cannot establish the direction, size, or precision of any difference in score change. It cannot show whether individual participants improved, remained similar, or worsened, and it cannot indicate how consistently outcomes varied across participants. No claim about clinical importance can be assessed without the observed estimates and an appropriate interpretation framework. The outcome definition and planned follow-up are not substitutes for results.
The safety counts indicate that adverse events were recorded in both groups, including serious adverse events in the Investigational Study Product group and none in the Reference Product group. These descriptive entries alone do not establish causality or comparative risk. The registry does not report event narratives, a statistical comparison, or enough detail to explain the safety populations. The absence of recorded deaths in these entries should not be interpreted beyond what is listed for the recorded groups.
General statistical interpretation: randomized allocation can strengthen a treatment comparison when the randomization process is implemented and the analysis is appropriate, but it does not eliminate uncertainty or missing-data concerns. Here, the record does not report the analysis plan, primary endpoint estimates, endpoint-analysis population, or missing-data methods. It therefore supports a description of the study question and selected safety counts, but not an efficacy conclusion. Readers should distinguish what the study set out to measure from what the registry actually reports as results.
13. Why This Trial Matters Statistically
This trial raises several statistical issues that are common in clinical research. The comparison uses two preparations of the same named product, so the question concerns the reconstitution volumes and procedures described in the record, not a comparison with no treatment. The primary endpoint is a graded facial assessment recorded at baseline and follow-up. Interpreting a mean change requires knowing how the scale measurements were combined and analyzed, including how the two sides of the face were handled. Those analysis details are not reported.
The registry also lists a broad set of secondary outcomes covering evaluator assessments, participant assessments, and satisfaction. Multiple outcomes can answer different questions, but they also create a need for a clear analysis hierarchy and careful interpretation of repeated testing. The registry record does not report how multiplicity was handled or which secondary outcomes were intended to support confirmatory claims. Without numerical estimates, readers cannot evaluate consistency across these different measures.
Another important issue is the distinction between enrollment and analyzed participants. Enrollment is 80, while the safety groups have denominators of 59 and 21. The record does not explain the relationship between those figures or provide the primary endpoint analysis population. Transparency about participant flow and missing observations is needed to understand how much information contributed to an estimate.
Finally, the primary endpoint is described with a 95% confidence interval, but the numerical result is not reported. A defined endpoint and a stated uncertainty measure are valuable parts of reporting only when the estimates and analysis details are available for interpretation. The record illustrates why a trial’s design and outcome definitions should be distinguished from its findings: the former are described, while the latter are not numerically available for the primary effectiveness question.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The principal limitation for statistical interpretation is that numerical results for the primary effectiveness endpoint are not reported in the registry record. There is no mean change, confidence interval, or treatment-group contrast to evaluate. The endpoint definition states the intended measure and follow-up, but does not establish an observed effect. Numerical results for the listed secondary outcomes are also not reported.
Important analysis information is absent. The statistical model, primary analysis population, approach to the two facial sides, handling of missing outcome data, and adjustment for multiple outcomes are not reported in the registry record. Randomization and evaluator blinding are stated, but procedural details such as sequence generation, allocation concealment, and the identity of masked parties are not reported. The safety denominators differ, and the record does not explain the reason or define their relationship to enrollment and analysis populations.
The registry describes the outcome as a mean change on a scale graded from 0 to 5, but does not report the distribution of scores or the variability of individual responses. It also does not provide additional information about the interpretation of a given change in score. The record’s summary of top serious adverse event terms is limited; timing, narratives, relatedness, and event-level detail are not reported. Accordingly, the available safety counts are descriptive and cannot support a causal interpretation.
The record identifies planning illustrations based on the observed effect, but it does not report the original protocol’s sample-size justification. The calculations’ stated assumptions should not be mistaken for evidence about the trial’s original design or observed power. Together, these reporting gaps prevent a complete assessment of effectiveness, precision, missingness, and the robustness of statistical conclusions.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds. — NCT03780244.
- Registry record last updated 2022-11-14; status last verified 2022-10.
- Results first posted 2022-11-14.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes a completed randomized, parallel, single-masked, multicenter study of Sculptra Aesthetic for nasolabial folds. The official title specifies evaluator blinding. The comparison was between product reconstituted with 8ml sterile water for injection and product reconstituted with 5ml. Enrollment was 80, and the study dates are 2018-12-18 to primary completion on 2020-02-28.
The primary outcome was change in Wrinkle Assessment Scale score from baseline at 48 weeks after the first treatment session, measured on both sides of the face. The registry describes the scale as ranging from 0 to 5 and specifies a 95% confidence interval for the mean. However, the numerical primary outcome result and comparison are not reported in the registry record. Safety entries include serious and other adverse events by group, with deaths recorded as 0 in both groups. Analysis methods, missing-data procedures, and multiplicity handling are not reported.